readthroughSign in
Oct 16, 2026Weekly roundupUpdated

Merck registers Phase 3 ovarian cancer and COPD trials; GT103/Keytruda NSCLC trial results posted

A terminated GT103 combination study reported results while Merck opened new Phase 3 programs in ovarian cancer and COPD and a Phase 1b/2 solid tumor study.

The week's Merck-linked activity included one completed readout and four new or ongoing trial registrations spanning oncology and respiratory disease.

  • A Phase 2 trial combining GT103 with pembrolizumab (Keytruda) in relapsed or refractory metastatic non-small cell lung cancer was terminated after completion of a planned interim analysis of 21 patients.1 Merck Sharp & Dohme LLC is a collaborator, with Ryan Dackor as lead sponsor, and results were first posted on 2026-10-14.1
  • Merck registered a Phase 3 trial of raludotatug deruxtecan (R-DXd, MK-5909), with or without bevacizumab, versus platinum-based chemotherapy in advanced platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer progressing after first-line PARP inhibitor maintenance. The study, known as ENGOT-ov107/GOG-3142/REJOICE-Ovarian05, is designed with an estimated enrollment of 646 participants2 and has an actual start date of 2026-10-07, with Daiichi Sankyo as a collaborator.2
  • Merck also registered a Phase 3 trial of ensifentrine (MK-5884), called ENHANCE-3, testing the inhaled therapy against placebo for preventing moderate or severe COPD exacerbations in adults on standard background treatment. The study is not yet recruiting, with an estimated enrollment of 2136 participants,3 and will evaluate efficacy and safety of ensifentrine versus placebo for the prevention of moderate and severe COPD exacerbation in adults with a history of exacerbations while on standard of care.3
  • A Phase 1b/2 study of MK-2750, an antibody drug conjugate, in advanced solid tumors including NSCLC, pancreatic, colorectal, esophageal, gastric, and head and neck cancers was registered. The trial is not yet recruiting, with an estimated enrollment of 300 participants and a start date of 2026-11-16.4
  • MK-6255, a first-in-human biologic for advanced and recurrent endometrial and ovarian cancer, remains listed as Phase 1 with an estimated enrollment of 80 participants.5 The study's status is still not yet recruiting, as this trial is the first time researchers will give MK-6255 to people.5

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.